Statins are among the most widely prescribed drugs. They reduce atherosclerotic cardiovascular disease events and improve survival in patients with established disease. Recommendations virtually mandate statin use in secondary prevention and widely advocate use for primary prevention. Clinicians initiate statin therapy with the expectation that the patient will continue lifelong treatment. However, this is a tall order for many persons, and it is not surprising that discontinuation rates are relatively high (1–3). As reported in this issue, Zhang and colleagues (4) explored the frequency of discontinuing statins in 1 hospital system. Combining data from structured electronic medical records and electronic ...

References

  • 1. Ellis JJErickson SRStevenson JGBernstein SJStiles RAFendrick AMSuboptimal statin adherence and discontinuation in primary and secondary prevention populations. J Gen Intern Med2004;19:638-45. [PMID: 15209602] CrossrefMedlineGoogle Scholar
  • 2. Chodick GShalev VGerber YHeymann ADSilber HSimah Vet alLong-term persistence with statin treatment in a not-for-profit health maintenance organization: a population-based retrospective cohort study in Israel. Clin Ther2008;30:2167-79. [PMID: 19108805] CrossrefMedlineGoogle Scholar
  • 3. Degli Esposti LSaragoni SBatacchi PBenemei SGeppetti PSturani Aet alAdherence to statin treatment and health outcomes in an Italian cohort of newly treated patients: results from an administrative database analysis. Clin Ther2012;34:190-9. [PMID: 22284998] CrossrefMedlineGoogle Scholar
  • 4. Zhang HPlutzky JSkentzos SMorrison FMar PShubina Met alDiscontinuation of statins in routine care settings. A cohort study. Ann Intern Med2013;158:526-34. LinkGoogle Scholar
  • 5. Lemstra MBlackburn DCrawley AFung RProportion and risk indicators of nonadherence to statin therapy: a meta-analysis. Can J Cardiol2012;28:574-80. [PMID: 22884278] CrossrefMedlineGoogle Scholar
  • 6. Pittman DGFenton CChen WHaffner SPendergrass MRelation of statin nonadherence and treatment intensification. Am J Cardiol2012;110:1459-63. [PMID: 22877424] CrossrefMedlineGoogle Scholar
  • 7. Naderi SHBestwick JPWald DSAdherence to drugs that prevent cardiovascular disease: meta-analysis on 376,162 patients. Am J Med2012;125:882-7. [PMID: 22748400] CrossrefMedlineGoogle Scholar
  • 8. Jung KMcBean AMKim JAComparison of statin adherence among beneficiaries in MA-PD plans versus PDPs. J Manag Care Pharm2012;18:106-15. [PMID: 22380470] CrossrefMedlineGoogle Scholar
  • 9. Deambrosis PSaramin CTerrazzani GScaldaferri LDebetto PGiusti Pet alEvaluation of the prescription and utilization patterns of statins in an Italian local health unit during the period 1994-2003. Eur J Clin Pharmacol2007;63:197-203. [PMID: 17200832] CrossrefMedlineGoogle Scholar
  • 10. Mancini GBBaker SBergeron JFitchett DFrohlich JGenest Jet alDiagnosis, prevention, and management of statin adverse effects and intolerance: proceedings of a Canadian Working Group Consensus Conference. Can J Cardiol2011;27:635-62. [PMID: 21963058] CrossrefMedlineGoogle Scholar